231 related articles for article (PubMed ID: 36859267)
1. Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial.
Zhao Q; Xie R; Zhong W; Liu W; Chen T; Qiu X; Yang L
Cost Eff Resour Alloc; 2023 Mar; 21(1):19. PubMed ID: 36859267
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer.
Ye ZM; Xu Z; Li H; Li Q
Front Public Health; 2023; 11():1046424. PubMed ID: 36844853
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of pembrolizumab in combination with chemotherapy compared with chemotherapy alone as first-line treatment for patients with advanced biliary tract cancer in China.
Zheng Z; Fang L; Cai H
BMC Cancer; 2023 Sep; 23(1):823. PubMed ID: 37667230
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitor for patients with advanced biliary tract cancer: A cost-effectiveness analysis.
Zhu Y; Liu K; Zhu H
Liver Int; 2023 Oct; 43(10):2292-2301. PubMed ID: 37592868
[TBL] [Abstract][Full Text] [Related]
5. First-line tremelimumab plus durvalumab and chemotherapy
Liu W; Huo G; Chen P
Front Pharmacol; 2023; 14():1163381. PubMed ID: 37547328
[No Abstract] [Full Text] [Related]
6. Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status.
Liu G; Kang S; Wang X; Shang F
Front Oncol; 2021; 11():669195. PubMed ID: 33987103
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness evaluation based on two models of first-line atezolizumab monotherapy and chemotherapy for advanced non-small cell lung cancer with high-PDL1 expression.
Zhang C; Liu Y; Tan J; Tian P; Li W
Front Oncol; 2023; 13():1093469. PubMed ID: 36998459
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of camrelizumab combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in China.
Zhao Z; Chen T; Zhou Z; Guo R; Liu Q
BMJ Open; 2023 Dec; 13(12):e071832. PubMed ID: 38110377
[TBL] [Abstract][Full Text] [Related]
9. A Cost-Effectiveness Analysis of Gemcitabine plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan.
Tsukiyama I; Ejiri M; Yamamoto Y; Nakao H; Yoneda M; Matsuura K; Arakawa I; Saito H; Inoue T
J Gastrointest Cancer; 2017 Dec; 48(4):326-332. PubMed ID: 27785685
[TBL] [Abstract][Full Text] [Related]
10. Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness analysis.
Han J; Tian K; Yang J; Gong Y
Lung Cancer; 2020 Aug; 146():42-49. PubMed ID: 32512272
[TBL] [Abstract][Full Text] [Related]
11. First-Line Durvalumab in Addition to Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer: A U.S.-Based Cost-Effectiveness Analysis.
Lin S; Luo S; Gu D; Li M; Rao X; Wang C; Huang P; Xu X; Weng X
Oncologist; 2021 Nov; 26(11):e2013-e2020. PubMed ID: 34431578
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers' perspective.
Tong YH; Ding HY; Xin WX; Zhong LK; Xu GQ; Zhang B; Yang GN; Fang L
Tumori; 2022 Feb; 108(1):33-39. PubMed ID: 33511911
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Wu B; Chen H; Shen J; Ye M
Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of adding durvalumab to first-line chemotherapy for extensive-stage small-cell lung cancer in China.
Liu G; Kang S
Expert Rev Pharmacoecon Outcomes Res; 2022 Jan; 22(1):85-91. PubMed ID: 33627014
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of serplulimab in combination with cisplatin plus 5-fluorouracil chemotherapy compared to cisplatin plus 5-fluorouracil chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.
Lin YT; Zhou CC; Xu K; Zhang MD; Li X
Ther Adv Med Oncol; 2023; 15():17588359231213621. PubMed ID: 38028139
[TBL] [Abstract][Full Text] [Related]
16. Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis.
Huo G; Liu W; Kang S; Chen P
Front Pharmacol; 2023; 14():1131219. PubMed ID: 36865925
[No Abstract] [Full Text] [Related]
17. Cost-effectiveness of analysis serplulimab plus chemotherapy as first-line therapy for PD-L1-positive advanced esophageal squamous cell carcinoma.
Zheng H; Li J; Wen F; Su N
Front Oncol; 2023; 13():1216960. PubMed ID: 38023250
[TBL] [Abstract][Full Text] [Related]
18. Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis.
Liang X; Chen X; Li H; Liu X; Li Y
Front Public Health; 2023; 11():1054405. PubMed ID: 36923040
[TBL] [Abstract][Full Text] [Related]
19. Durvalumab consolidation therapy in patients with stage III non-small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis.
Chen X; Yang Z; Xiang G; Gu L; Qi Z; Wan B; Lu Y; Chang F; Zhu Y
Expert Rev Pharmacoecon Outcomes Res; 2022 Jun; 22(4):647-654. PubMed ID: 34643129
[TBL] [Abstract][Full Text] [Related]
20. Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model.
Rui M; Shi F; Shang Y; Meng R; Li H
Adv Ther; 2020 Sep; 37(9):3761-3774. PubMed ID: 32647912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]